Email
Password
Remember meForgot password?
    Log in with Twitter
Press Release

May 3, 2018 14:00 UTC

Cardiac Insight, Inc. to Showcase Industry-First Cardiac Devices for Atrial Fibrillation and Sudden Cardiac Arrest Risk Detection at Heart Rhythm 2018, Heart Rhythm Society’s 39th Annual Scientific Sessions, May 9-11, Exhibit 1071

KIRKLAND, Wash.--(Business Wire)--Cardiac Insight, Inc., a leading U.S. developer of wearable cardiac medical devices and diagnostic software systems with proprietary algorithms, announced today the company will showcase its innovative solutions for the first time at Heart Rhythm Society’s 39th Annual Scientific Sessions. Heart Rhythm 2018 will be held May 9-11, 2018 in the Boston Convention and Exhibition Center (https://www.hrssessions.org).

Cardiac Insight will present live interactive demonstrations of its Cardea SOLO™, a wearable, wire-free 7-day ECG Sensor and PC-based, in-office Analysis Software System for the detection of adult arrhythmias, including atrial fibrillation (AFib), and Cardea 20/20 ECG™, a 12-lead test for identification of the risk of Sudden Cardiac Arrest in young athletes, at the event’s main convention hall, Exhibit 1071.

Case studies will be presented that illustrate how Cardiac Insight’s differentiated approach is helping clinicians achieve earlier diagnosis of challenging cardiac arrhythmias such as atrial fibrillation in adults, and life-threatening, but often clinically silent arrhythmias and underlying cardiac disease in young athletes.

Heart Rhythm 2018 attendees are also invited to participate in Cardiac Insight’s special book-signing event for HEART STORIES, a collection of personal essays about patients and the great pioneers who saved them, authored by renowned cardiologist, former President of the Heart Rhythm Society and Cardiac Insight Scientific Advisory Board Chair Robert G. Hauser, MD. Book signings will take place in the company Exhibit 1071 on:

  • May 9 – 5-6pm
  • May 10 – 10am-11am; 2-3pm
  • May 11 – 11am-12pm; 2:30-3:30pm

“Our differentiated frontline solutions, that address challenging cardiac arrhythmia diagnoses, are rapidly gaining recognition by some of the world’s top cardiologists and researchers,” said Brad Harlow, Chief Executive Officer of Cardiac Insight, Inc. “Heart Rhythm 2018 will help ensure more of the industry’s premier cardiologists, electrophysiologists and cardiac researchers are aware of our game-changing technology, and will also provide us the opportunity to gain valuable market insights to best serve arrhythmia healthcare professionals well into the future.”

The Cardea SOLO System leverages one of Cardiac Insight’s main differentiators – its proprietary ECG Analysis Software that incorporates advanced arrhythmia detection algorithms. Cardea SOLO streamlines ambulatory patient diagnosis at the point of care, and eliminates the need for costly and time-consuming outsourced ECG scanning services.

Cardea SOLO is the ONLY in-office PC-based ECG Analysis Software cleared by the U.S. Food and Drug Administration (FDA) to produce an automated draft findings report without human intervention. The report is ready for clinician review or edits in five minutes or less. Cardea SOLO Software also provides clinicians access to and ownership of every heartbeat of patient data for further analysis.

The Heart Rhythm Society’s 39th Annual Scientific Sessions convenes the finest clinicians, scientists, researchers and innovators in the field of cardiac pacing and electrophysiology. More than 800 of the world’s most noted experts in cardiac rhythm management serve as faculty for more than 240 educational sessions while more than 130 exhibitors showcase innovative products and services.

Millions of adults across the United States and Europe suffer from arrhythmia in its most common form, atrial fibrillation (AFib). Patients with AFib face an estimated five-times higher risk of stroke and more than double their risk of Sudden Cardiac Death. In young adult athletes, Sudden Cardiac Arrest is the number one medical cause of death; it is estimated that every 72 hours an athlete dies in the U.S. from cardiac arrest.

About Cardiac Insight, Inc.

Cardiac Insight, Inc. (www.cardiacinsightinc.com) is a leading U.S. developer of advanced body-worn digital health care information systems through its proprietary software, algorithms and devices. The company’s two flagship products are its wearable ECG Sensor and Analysis Software System, Cardea SOLO™ (www.cardeasolo.com), and Cardea 20/20 ECG™, the only 12-lead test that incorporates the International Criteria for identification of the risk of Sudden Cardiac Arrest in young athletes. Founded in 2008, Cardiac Insight is an ISO-certified company and is based in Kirkland, Washington, USA.

For Cardiac Insight, Inc.
Teresa Fausti, 425-503-5674
teresa@fausticommunications.com